Abatacept Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Overview of Rheumatoid Arthritis-Associated Interstitial Lung Disease and Its Treatment
Semin Respir Crit Care Med DOI: 10.1055/s-0044-1782218Interstitial lung disease (ILD) is a common pulmonary complication of rheumatoid arthritis (RA), causing significant morbidity and mortality. Optimal treatment for RA-ILD is not yet well defined. Reliable prognostic indicators are largely byproducts of prior ILD progression, including low or decreasing forced vital capacity and extensive or worsening fibrosis on imaging. In the absence of validated tools to predict treatment response, decisions about whether to initiate or augment treatment are instead based on clinical judgment. In general, treatment should be initiate...
Source: Seminars in Respiratory and Critical Care Medicine - March 14, 2024 Category: Respiratory Medicine Authors: Pugashetti, Janelle Vu Lee, Joyce S. Tags: Review Article Source Type: research

Long Term Follow-Up Of Abatacept, Post-Transplantation Cyclophosphamide and Sirolimus (AbaCyS) based Haploidentical Transplantation in Younger Patients with Nonmalignant Diseases
Haploidentical (Haplo) HCT for nonmalignant diseases (NMD) faces inherent challenges of both alloreactivity and graft failure. Building upon promising results from pilot studies, where abatacept was combined with post-transplantation cyclophosphamide (PTCy) and sirolimus (AbaCyS) in younger NMD patients undergoing haplo-HCT, we present the long-term outcomes of this protocol. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - March 13, 2024 Category: Hematology Authors: Sarita Rani Jaiswal, Mahak Agarwal, Gitali Bhagawati, Bhudev Chandra Das, Prakash Baligar, Manoj Garg, Subhrajit Biswas, Suparno Chakrabarti Source Type: research

Long-Term Follow-Up of Abatacept, Post-Transplantation Cyclophosphamide, and Sirolimus-Based Haploidentical Transplantation in Younger Patients with Nonmalignant Diseases
Haploidentical (haplo) hematopoietic cell transplantation (HCT) for nonmalignant disease (NMD) carries inherent challenges of both alloreactivity and graft failure. Building on promising results from pilot studies in which abatacept was combined with post-transplantation cyclophosphamide (PTCy) and sirolimus (AbaCyS) in younger NMD patients undergoing haplo-HCT, we present the long-term outcomes of this protocol. On the back of uniform disease-specific conditioning regimens containing antithymocyte globulin 4.5 mg/kg from day -9 to day -7, GVHD prophylaxis with AbaCyS consisted of abatacept administered on days 0, +5, +20,...
Source: Biology of Blood and Marrow Transplantation - March 13, 2024 Category: Hematology Authors: Sarita Rani Jaiswal, Mahak Agarwal, Gitali Bhagawati, Bhudev Chandra Das, Prakash Baligar, Manoj Garg, Subhrajit Biswas, Suparno Chakrabarti Tags: Haploidentical Source Type: research

Mycosis fungoides-like eruptions associated with abatacept
Australas J Dermatol. 2024 Mar 7. doi: 10.1111/ajd.14249. Online ahead of print.NO ABSTRACTPMID:38454790 | DOI:10.1111/ajd.14249 (Source: The Australasian Journal of Dermatology)
Source: The Australasian Journal of Dermatology - March 8, 2024 Category: Dermatology Authors: Daichi Hoshina Yuri Nagata Source Type: research

Two-year treatment persistence with subcutaneous abatacept in rheumatoid arthritis: results from the French cohort of the ASCORE study
CONCLUSIONS: In current practice in France, the rate of subcutaneous abatacept persistence at 2 years was comparable with that of the intravenous form. Treatment persistence was higher when abatacept was used as first-line versus later-line biologic therapy.PMID:38436358 | DOI:10.55563/clinexprheumatol/ddx0fz (Source: Clinical and Experimental Rheumatology)
Source: Clinical and Experimental Rheumatology - March 4, 2024 Category: Rheumatology Authors: Ren é-Marc Flipo Arnaud Constantin Philippe Goupille M élanie Chartier Ana ël Ohayon Xavier Mariette Source Type: research

Abatacept Could Prevent Progression to Rheumatoid Arthritis
Abatacept, a biologic used to treat rheumatoid arthritis (RA), staved off the disease in people who were at high risk for the condition, according to results from a randomized clinical trial that involved 213 participants from the Netherlands and the UK. (Source: JAMA - Journal of the American Medical Association)
Source: JAMA - Journal of the American Medical Association - February 28, 2024 Category: General Medicine Source Type: research

Analyzing the risk of osteoporosis and fracture in rheumatoid arthritis patients who have been treated with various biologics
ConclusionThe treatment option has emerged as a critical determinant in the context of future osteoporosis and osteoporotic fracture risks among RA. These findings offer a valuable resource for clinicians, empowering them to tailor bespoke treatment strategies for RA patients, thereby mitigating the potential for future osteoporosis and fractures. (Source: International Journal of Rheumatic Diseases)
Source: International Journal of Rheumatic Diseases - February 9, 2024 Category: Rheumatology Authors: Yu ‐Jih Su, Chun‐Yu Lin, Chung‐Yuan Hsu Tags: ORIGINAL ARTICLE Source Type: research

Comparative effectiveness of biologics in patients with rheumatoid arthritis stratified by body mass index: a cohort study in a Swiss registry
Conclusions No differences in DAS28-remission were found between the study drugs and adalimumab as first biologic in patients with RA, independently of the BMI cohort. We did not find evidence that treatment with abatacept increased the likelihood of remission compared with adalimumab among obese patients with RA. (Source: BMJ Open)
Source: BMJ Open - February 8, 2024 Category: General Medicine Authors: Vallejo-Yagüe, E., Burkard, T., Finckh, A., Burden, A. M., On behalf of the clinicians and patients of the Swiss Clinical Quality Management Program Tags: Open access, Rheumatology Source Type: research